Effects of mangesium salts and their combination with vitamin B6 on oxalates crystalluria in alimentary deficiency of piridoxine
- 作者: Spasov AA1, Iezhitsa IN1, Kharitonova MV1, Kravchenko MS1, Spasov AA1, Iezhitsa IN1, Kharitonova MV1, Kravchenko MS1
-
隶属关系:
- 期: 编号 3 (2009)
- 页面: 22-26
- 栏目: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/277376
- ID: 277376
如何引用文章
全文:
详细
We studied the effects of oral magnesium (Mg) salts either alone or in combination with pyridoxine hydrochloride in rats on pyridoxine-deficient diet. Fifty-four male rats were randomized into two groups and were fed either a standard diet or a pyridoxine-deficient diet for 3 weeks. A significant rise of the EGOT index ( > 1.5), oxaluria (from 74.8 ± 5.2 to 117.9 ± 12.3 mcM/l, p = 0.035), and crystalluria in rats fed with pyridoxine deficient diet were revealed. Oral Mg chloride, Mg L-aspartate either alone or in combination with pyridoxine in comparison with magnesium sulfate, magne B6 (Mg lactate with pyridoxine) and pyridoxine alone were administered (50 mg of magnesium and/or 5 mg of pyridoxine per kg body weight). Magnesium salts in combination with pyridoxine lowered an oxalate level and crystalluria whereas magnesium salts alone reduced only crystalluria. Antilithis effects of Mg L-aspartate and Mg chloride in combination with pyridoxine were comparable with those observed in magne B6 or pyridoxine treatment and were significantly higher than in magnesium sulfate treatment.
参考
- Гурвич Д. Б., Коровина Н. А., Мырсова Л. И. Влияние диеты, обогащенной магнием, на экскрецию оксалатов и функциональное состояние почек у больных с гипероксалурией. Педиатрия 1979; 2: 14-16.
- Prien E. L., Gershoff S. N. Magnesium oxide-pyridoxine therapy for recurrent calcium oxalate calculi. J. Urol. (Baltimore) 1974; 112: 509.
- Firoz M., Graber M. Bioavailability of US commercial magnesium preparations. Magnes. Res. 2001; 14 (4): 257-262.
- Iezhitsa I. N., Spasov A. A., Kravchenko M. S. et al. Comparative study of magnesium salts' bioavailability in rats fed with magnesium-deficient diet. J. Jpn. Soc. Magnes. Res. 2006; 25 (2): 99.
- Сивориновский Г. А. Количественное определение щавелевой кислоты в моче. Лаб. дело 1969; 7: 401-404.
- Меньшиков В. В., Делекторская Л. Н., Золотнинская Р. М. Лабораторные методы исследования в клинике: Справочник. М.: Медицина; 1987. 266-267.
- Allegra A., Corica F., Ientile R. et al. Plasma (total and ionized), erythrocyte and platelet magnesium levels in renal transplantant recipients during cyclosporine and/or azathioprine treatment. Magnes. Res. 1998; 11 (1): 11-18.
- Garsia-Rodriguez M. B., Peres-Garsia C. C., Rios-Granja M. A. et al. Renal handling of calcium and phosphorus in experimental renal hyperparathyroidism in dogs. Vet. Res. 2003; 34: 379-387.
- Рыбина И. Л., Вощула В. И. Оценка роли метаболизма оксалата в этиопатогенезе мочекаменной болезни. БМЖ. 2006; 1: 15.
- Leklem J. E. Vitamin B-6: A status report. J. Nutr. 1990; 120 (11S): 1503-1507.
- Monico C. G., Persson M., Ford G. C. et al. Potential mechanisms of marked hyperoxaluria not due to primary hyperoxaluria I or II. Kidney Int. 2000; 62 (2): 392-400.
- Cochat P., Liutkus A., Fargue S. et al. Primary hyperoxaluria type 1: till challenging! Pediatr. Nephrol. 2006; 21 (8): 1075-1081.
- Khan S. R., Shevock P. N., Hackett R. L. Magnesium oxide administration and prevention of calcium oxalate nephrolithiasis. J. Urol. (Baltimore) 1993; 149: 412-416.